Rapid Virologic Suppression With Dolutegravir Plus Lamivudine Facilitates Early Switch to Long-Acting Cabotegravir Plus Rilpivirine for Treatment-Naive People With HIV-1: Month 11/12 Outcomes From the Phase 3b VOLITION Study
Córdova, Ezequiel; Rolle, Charlotte-Paige; Hove, Kai; Felizarta, Franco; Johnson, Marc; Cuevas-Tascon, Guillermo; Molina, Jean-Michel; Bravo-Urbieta, Joaquín; Hocqueloux, Laurent; Lupo, Sergio; Pérez, Carlos-M; Ole-Jensen, Bjorn-Erik; Jonsson-Oldenbuttel, Celia; Zamora-Vargas, Francisco-Xavier; Szabo, Jason; Cahn, Pedro; Antinori, Andrea; López-Bernaldo-de-Quiros, Juan-Carlos; Castagna, Antonella; Bui, Monika; Grove, Richard; Wang, Kehui; St-Clair, Marty; Moodley, Riya; Radford, Jacob; Priest, Julie; Gutner, Cassidy-A; Jacob, Ian; Chatterjee, Avishek; Somvanshi, Suryakant; Kolobova, Irina; Trehan, Rekha; Polk, Christopher; Patel, Parul; de-los-Rios, Patricia; DiMondi, Paul; Gordon, Lori-A; Brown, Kimberley; Garges, Harmony-P; Jones, Bryn; van-Wyk, Jean
Fecha:
2026-09-01
Mostrar el registro completo del ítem